Peter Joyce

Peter Joyce

Company: Grey Wolf Therapeutics Ltd.

Job title: Chief Executive Officer & Co-founder


ERAP1 Inhibition to Generate Neoantigens & Drive Anti-Tumour Cell Killing 12:00 pm

Targeting the endoplasmic reticulum in the antigen presentation pathway to create novel neoantigens in cancer Increasing tumour visibility and extending the therapeutic benefit of immunotherapy to many more cancer patients Presenting Grey Wolf’s 1st in class ERAP1 inhibitor as a therapeutic pipeline for opportunitiesRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.